Survodutide is an investigational dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Unlike tirzepatide (GIP/GLP-1), survodutide combines glucagon and GLP-1 agonism, adding glucagon-driven hepatic fat oxidation and energy expenditure to GLP-1-mediated appetite suppression. It has shown particular promise for MASH (metabolic dysfunction-associated steatohepatitis), achieving MASH resolution in 83% of patients at the highest dose in Phase 2, and is in Phase 3 trials for both obesity and MASH.
6 vendors tracked by PeptideAtlas list Survodutide, priced from $80.00 to $110. The lowest price per milligram is $4.75/mg at PureRx Peptides (20MG). 4 independent Janoshik purity tests cover Survodutide across 4 vendors. Results range from 98.3% to 99.9%.
Category: Metabolic / Dual Agonist. Evidence rating: B (meaningful human data).
Clinical status: Phase 3 clinical trials for MASH and obesity (Boehringer Ingelheim)
Survodutide simultaneously activates glucagon receptors (increasing hepatic fat oxidation, energy expenditure, and thermogenesis) and GLP-1 receptors (reducing appetite, slowing gastric emptying, improving insulin secretion). The glucagon component specifically drives hepatic lipid mobilization —…
Research base: 33 registered clinical trials and 40 indexed publications reference Survodutide.
Safety considerations: GI adverse events (nausea, vomiting, diarrhea) similar to other incretin-based therapies; Heart rate increases observed (class effect); Dose-dependent tolerability — titration essential.
Reviewed by the PeptideAtlas Editorial Team.
| Half-life | ~5-6 days (allows once-weekly dosing) |
|---|---|
| Production method | synthetic |
| Anti-doping status | not-listed |
| US regulatory status | Not FDA-approved. Phase 3 trials ongoing for MASH and obesity. Breakthrough therapy designation for MASH. |
| Vendor | Size | Price | Price per mg |
|---|---|---|---|
| PureRx Peptides | 20MG | $95.00 | $4.75/mg |
| Red Fox Peptides | 10 mg | $80.00 | $8.00/mg |
| Wholesale Peptide | 10mg | $84.99 | $8.50/mg |
| Orbitrex Peptides | 10mg | $99.99 | $10.00/mg |
| Growth Guys | 10mg | $100 | $10.00/mg |
| Protide Health | 10mg | $110 | $11.00/mg |
| Vendor | Best tested purity |
|---|---|
| Polaris Peptides | 99.9% |
| uwa-biotech | 99.5% |
| Inno Peptides | 99.5% |
| Qingdao Sigma Chemical QSC | 98.3% |
Survodutide is a glucagon/GLP-1 dual agonist. Tirzepatide is a GIP/GLP-1 dual agonist. Retatrutide is a GIP/GLP-1/glucagon triple agonist. Survodutide's glucagon component specifically targets liver fat, making it particularly promising for MASH. Retatrutide includes all three mechanisms.
Survodutide is a dual GLP-1 and glucagon receptor agonist being researched as a next-generation weight loss peptide with potential liver health benefits.
SURVODUTIDE has been studied for: Weight loss research, Dual mechanism, Liver health potential. GLP-1/glucagon dual agonist; emerging weight loss research.
Dual agonist that combines GLP-1 appetite suppression with glucagon's fat-burning and hepatic effects.
Vendors with independent lab tests for it: Polaris Peptides.
Vendors stocking it: Zztai Peptide, ZePeptide, Wholesale Peptide, PureRx Peptides, Protide Health, utherpeptide, Uther, Growth Guys, Toronto Peptides, Montreal Peptides, Orbitrex Peptides.
Coverage on this site: Natural GLP-1 activator Calocurb shows weight loss with muscle preservation, Survodutide Shows Renal and Metabolic Gains in DKD Mouse Model at ECO 2026, Daily Pill Could Tackle Dreaded Ozempic Rebound, Orforglipron May Transform Obesity Treatment Approach.